As one of the primary mechanisms by which dopamine signaling is regulated, the dopamine transporter (DAT) is an attractive pharmacological target for the treatment of diseases based in dopaminergic dysfunction. In this work we demonstrate for the first time that the commonly prescribed breast cancer therapeutic tamoxifen and its major metabolites, 4-hydroxytamoxifen and endoxifen, inhibit DAT function. Tamoxifen inhibits [ 3 H]dopamine uptake into human DAT (hDAT)-N2A cells via an uncompetitive or mixed mechanism. Endoxifen, an active metabolite of tamoxifen, asymmetrically inhibits DAT function in hDAT-N2A cells, showing a preference for the inhibition of amphetamine-stimulated dopamine efflux as compared to dopamine uptake. Importantly, we demonstrate that the effects of tamoxifen and its metabolites on the DAT occur independently of its activity as selective estrogen receptor modulators. This work suggests that tamoxifen is inhibiting DAT function through a previously unidentified mechanism.
The dopamine transporter (DAT) is a key mechanism by which dopamine is removed from the extracellular space following its release from neurons, and as such plays a vital role in the regulation of dopamine signaling. Pharmacological modulation of the DAT, therefore, is a source of great interest for the treatment of multiple dopaminergic diseases.
The breast cancer therapeutic tamoxifen is a wellestablished pharmaceutical agent with a clear safety profile; however, tamoxifen has multiple actions beyond its original designation as a selective estrogen receptor modulator (SERM) . Various studies have demonstrated that tamoxifen can modulate the dopaminergic system. For example, tamoxifen inhibits amphetamine-stimulated hyperactivity in rodents, potentially through inhibition of protein kinase C (Einat et al. 2007) . Tamoxifen also has efficacy as a neuroprotectant in models of dopaminergic neurotoxicity (Obata and Kubota 2001; Bourque et al. 2007) . However, the mechanism by which tamoxifen affects the dopaminergic system remains incompletely elucidated.
Estrogen is well-known to affect DAT function; it stimulates dopamine efflux and enhances amphetaminestimulated dopamine efflux (Becker 1990; Xiao et al. 2003) . There are three known estrogen receptors: ERa, ERb, and the G-protein-coupled estrogen receptor (GPER1). All three receptors modulate DAT function to varying degrees (Alyea et al. 2008; Alyea and Watson 2009 ). Beyond its SERM activity at ERa and ERb, tamoxifen is also an agonist at GPER1 (Thomas et al. 2005) .
Tamoxifen is metabolized into three active metabolites that reach appreciable levels in the brain: 4-hydroxytamoxifen, Ndesmethyltamoxifen, and 4-hydroxy-N-desmethyltamoxifen (known as endoxifen). 4-Hydroxytamoxifen and endoxifen are considered the active metabolites of tamoxifen, because their potency as SERMs is 100-fold higher than the parent compound (Lien et al. 1991) . Any combination of these metabolites could be responsible for the effects of tamoxifen on the dopaminergic system.
In this study we hypothesized that tamoxifen would inhibit function of the dopamine transporter. We demonstrate for the first time that tamoxifen inhibits DAT function through an uncompetitive or mixed mechanism. We also determine that two of tamoxifen's active metabolites, 4-hydroxytamoxifen and endoxifen also inhibit transporter function. Through blockade of the estrogen receptors with selective antagonists, we confirm that tamoxifen and its metabolites inhibit DAT function independently of their actions at any of the estrogen receptors.
Methods

Materials
All chemicals were obtained from Sigma Aldrich with the exception of [ 3 H]dopamine, which was purchased from Perkin Elmer (Waltham, MA, USA), and G36, which was purchased from Tocris (Minneapolis, MN, USA). Tamoxifen citrate, endoxifen, 4-hydroxytamoxifen, and G36 were prepared as a 50 mM stock and fulvestrant as a 10 mM stock in dimethylsulfoxide. Stock solutions were diluted in the buffers appropriate for the assay. Final concentration of dimethylsulfoxide in all solutions ranged from 0.01 to 0.03% and were kept constant across all conditions within an experiment.
Cell culture N2 mouse neuroblastoma cells stably expressing the human DAT (hDAT-N2a) cells were grown in Optimem reduced serum media (Gibco, Rockville, MD, USA) supplemented with fetal bovine serum (10%), penicillin-strepavidin (1%), and G418 (100 lg/mL; Gibco) at 37°C in 5% CO 2 . For experiments involving estrogen receptor antagonists, cells were maintained under the same conditions and in a similar media formulation except that the Optimem was free of phenol-red and was supplemented with a charcoalstripped bovine serum (kindly provided by Dr. James Rae, University of Michigan) to limit exposure of the cells to exogenous estrogens. For assays measuring dopamine uptake and amphetamine-stimulated dopamine efflux, cells were trypsinized 1-2 days before the experiment and seeded on 24-well plates (50 000-100 000 cells per well); at the time of the experiment, cell density approached confluency with approximately 200,000 cells per well. All experiments were carried out in triplicate and repeated with at least three different cultures of the cells. All experiments were carried out in concordance with the safety guidelines of the University of Michigan.
[ 3 H]Dopamine uptake Cells were grown in 24-well plates. Media was aspirated from the wells and cells were washed three times with Krebs Ringer HEPES buffer (KRH, pH 7.4, 25 mM HEPES, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH 2 PO 4 , 1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 5.6 mM glucose, 50 lM pargyline, and 50 lM ascorbic acid) before the addition of 400 lL of drug or vehicle in KRH. Vehicle or drugs were present throughout the experiment. All experiments were conducted at 23°C. After a 1-h incubation with vehicle or drugs, 100 lM cocaine was added to non-specific wells, and [ 
Measurement of surface DAT by biotinylation
hDAT-N2A cells were incubated with 3 lM tamoxifen in KRH for 1 h. The amount of cell surface DAT was determined in these cells with biotinylation using previously described method (Guptaroy et al. 2009 ) with minor modifications. Avidin beads (80 lL) were used to pull down biotinylated cell surface proteins from cells lysates (400 lg). Total and biotinylated fraction of DAT was measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using anti-DAT antibody.
Statistical analysis
Statistical analyses were carried out using Graphpad Prism 6 (San Diego, CA, USA). Data are plotted as mean AE the standard error of the mean (SEM). Significance was set at p < 0.05. Comparisons between multiple groups were made with one-way analysis of variants (ANOVA), with post hoc Dunnett's multiple comparison test. Non-linear regression was used to determine IC 50 , V max , and K m values. Calculated K m and V max values were compared across experiments by a one-way ANOVA. Kinetic data for tamoxifen were also analyzed using Line-weaver Burke analysis in Prism 6. When concentration response curves were compared, comparison of fits in non-linear regression was used to determine whether curves differed from each other. The null hypothesis was that the best-fit parameter for the value did not differ.
Results
Tamoxifen and the active metabolites 4-hydroxytamoxifen and endoxifen inhibit amphetamine-stimulated dopamine efflux and dopamine uptake in hDAT-N2A cells To characterize the effects of tamoxifen on DAT function, we quantified [ 3 H]dopamine uptake and amphetaminestimulated [
3 H]dopamine efflux in hDAT-N2A cells following 1-h pre-treatment with the increasing concentrations of tamoxifen (Fig. 1a) . One-way repeated measures ANOVA indicated a significant effect of tamoxifen treatment on Post hoc Dunnett's multiple comparisons test revealed a significant decrease in dopamine uptake for 3 lM (p < 0.001) and 10 lM (p < 0.0001) tamoxifen and a significant decrease in dopamine efflux for 0.3 lM (p < 0.001), 3 lM (p < 0.01), and 10 lM (p < 0.0001) tamoxifen compared to vehicle. There was no significant difference between the concentration response curves generated for dopamine uptake and amphetamine-stimulated dopamine efflux in hDAT-N2A cells (Fig. 1a) . See Table 1 for IC 50 values.
The effects of the active metabolites of tamoxifen on the DAT were characterized. N-desmethyltamoxifen had no effect on [ 3 H]dopamine uptake or efflux through the DAT at concentrations up to 3 lM, but was cytotoxic at higher concentrations as measured by PrestoBlue (ThermoFisher, Wayne, MI, USA data not shown). Tamoxifen and the two remaining metabolites, 4-hydroxytamoxifen and endoxifen were not toxic at any of the concentrations tested; therefore our focus was on these three compounds.
In hDAT-N2A cells, a repeated measures one-way ANOVA indicated a significant effect of 4-hydroxytamoxifen treatment on [ 3 H]dopamine uptake (F(5, 15) = 33.68, p < 0.0001) and efflux (F(5, 10) = 31.63, p < 0.0001) (Fig. 1b) . Post hoc Dunnett's multiple comparisons test revealed a significant decrease in [ 3 H]dopamine uptake for 1 lM (p < 0.05), 3 lM (p < 0.0001) and 10 lM (0.0001) 4-hydroxytamoxifen and a significant decrease in amphetamine-stimulated [ 3 H]dopamine efflux for 3 lM (p < 0.001), and 10 lM (p < 0.0001) 4-hydroxytamoxifen compared to vehicle. The concentration response curves generated by these two datasets were not significantly different from each other.
A one-way repeated measures ANOVA indicated a significant effect of endoxifen treatment on [ (Table 1) .
Tamoxifen effect on dopamine uptake kinetics
To further investigate the action of tamoxifen at the DAT, we determined the effects of tamoxifen on [ 3 H]dopamine uptake kinetics in hDAT-N2A cells. Tamoxifen significantly Uptake 4.4 lM (3.0-6.3) 3.6 lM (2.5-5.0) 6.7 lM (3.7-12)*** Efflux 4.5 lM (2.7-7.4) 2.6 lM (1.8-3.7) 1.3 lM (0.9-1.9) ***p < .001 versus IC 50 for efflux.
decreased the V max of dopamine uptake at 3 lM and 10 lM. At 10 lM, tamoxifen also significantly decreased the K m of [ 3 H]dopamine uptake (Fig. 2a , Table 2 ). At 3 lM, tamoxifen significantly decreases the V max of dopamine uptake without having a significant effect on K m . Lineweaver-Burke analysis (inset, Fig. 2) indicates that the inhibition by 3 lM tamoxifen is uncompetitive, because V max /K m for individual vehicle versus 3 lM tamoxifen did not change (0.05 AE 0.004 vs. 0.045 AE 0.005 SEM, respectively). Analysis of inhibition by 10 lM tamoxifen showed mixed inhibition (V max /K m = 0.024 AE 0.007, p < 0.02 vs. vehicle). The reduction in [ 3 H]dopamine uptake was not because of a reduction in surface DAT (Fig. 2b) . Incubation of hDAT-N2A cells with 3 lM tamoxifen for 1 h had no effect on surface levels of the DAT (2-tailed t-test, t = 1.020 df = 8, p = 0.337).
Effect of estrogen antagonists
N2A mouse neuroblastoma cells express all three known estrogen receptors (Mendez and Garcia-Segura 2006; Manthey et al. 2010; Su et al. 2012) . Because tamoxifen and its metabolites are SERMS, we sought to determine whether their actions on the DAT might be attributable to their activity at any of the three estrogen receptors. The hDAT-N2A cells used in these experiments were maintained in medium supplemented with charcoal stripped fetal bovine serum to preclude complications that might arise from the presence of exogenous estrogens. Using the ERa and ERb antagonist fulvestrant (3 lM), and the GPER1 antagonist G36 (10 lM), we found that blockade of the estrogen receptors had no significant effect on basal (Fig. 3) .
Discussion
In this study we demonstrate that tamoxifen and two of its active metabolites, 4-hydroxytamoxifen and endoxifen, impair DAT function independently of their actions at the estrogen receptors. We also demonstrate that in cells, tamoxifen impairs dopamine uptake through a mixed mechanism. This suggests that tamoxifen has a preference for binding to the substrate-occupied transporter indicating an allosteric mechanism of action.
In our investigation of the effects of tamoxifen and its metabolites on the DAT, it was necessary that we consider the potential effects of the drugs' SERM activity on DAT function. We found that antagonists of the estrogen receptors had no effect on amphetamine-stimulated dopamine efflux or dopamine uptake on their own, and did not alter the ability of tamoxifen or its metabolites to inhibit forward or reverse transport. By failing to antagonize the effects of tamoxifen and its metabolites on the DAT, these experiments demonstrated that tamoxifen is not exerting its effects on the DAT through an estrogenic mechanism. Furthermore, because the antagonists themselves had no effect on dopamine uptake or efflux, an antiestrogenic effect of tamoxifen or its metabolites is insufficient to explain its inhibition of DAT function. These conclusions are further supported by previous observations that fulvestrant but not tamoxifen is capable of antagonizing the effect of estrogen on amphetaminestimulated efflux (Xiao et al. 2003) . In addition, endoxifen and 4-hydroxytamoxifen are 100-fold more potent in their actions at the estrogen receptors, relative to tamoxifen (Lien et al. 1991) , but all of the compounds tested display IC 50 s in the micromolar range for reduction in DAT function. The diphenyl structural motif in tamoxifen and its metabolites could partially account for their blockade of dopamine uptake; this motif also exists in DAT blockers such as modafinil and benztropine (Schmitt et al. 2013) . Though tamoxifen and 4-hydroxytamoxifen exhibit similar effects on uptake and efflux our results indicate that endoxifen preferentially inhibits dopamine efflux in the cells. The difference between the effects of endoxifen on dopamine uptake and amphetamine-stimulated dopamine efflux in the cells is intriguing. In the cell-based assay in which [
3 H]dopamine is exogenously loaded, the [ 3 H]-dopamine efflux measured is actually the difference between the outward transport of dopamine and the amount of dopamine taken back up in to the cell during assay. Thus an inhibitor of dopamine uptake might be expected to display less of an effect on amphetamine-stimulated dopamine efflux, because the blockade of reuptake might obfuscate a reduction in efflux. This was not true of endoxifen, however. Another activity of endoxifen might play a role in the enhanced potency for reverse transport. Tamoxifen and its metabolites, including endoxifen, inhibit protein kinase C activity (O'Brian et al. 1985) . In cell-based assays, tamoxifen exhibits micromolar potency in the inhibition of phorbol myristate acetate-stimulated phosphorylation of protein kinase C (PKC) substrates (unpublished data). Our previous studies (Kantor and Gnegy 1998; Johnson et al. 2005) have shown that protein kinase C inhibitors reduce amphetamine-stimulated dopamine efflux but do not inhibit dopamine reuptake. Thus, at the concentrations tested here, it is reasonable to expect that tamoxifen and its metabolites are inhibiting PKC, although this may not contribute to the reduction in dopamine uptake. It is possible that the enhanced effectiveness of endoxifen in reducing dopamine efflux is because of a PKC-dependent inhibition of amphetamine-stimulated dopamine efflux, however. Reportedly, endoxifen is more potent at inhibiting PKC than is tamoxifen (Ali et al. 2010) .
This work demonstrates for the first time that tamoxifen inhibits function of the DAT independently of its actions as a selective estrogen receptor modulator. Future work will aim to better characterize the interaction between the DAT and tamoxifen and clarify a mechanism of action for these observations.
